论文部分内容阅读
目的:观察用贝前列素钠片联合缬沙坦治疗早期糖尿病肾病时,减少或逆转糖尿病肾病蛋白尿的效果。方法:选择48例早期糖尿病肾病患者,并将其随机分为试验组和对照组。所有患者均给予缬沙坦治疗,试验组另口服贝前列素钠。检测用药前后的BUN、Scr、24h UAlb、FBG、胰岛素、HbAlc等指标,并统计不良反应。结果:治疗前两组BUN、Scr、24h UAlb水平均无显著差异,治疗后本组内均较治疗前显著改善,且治疗后试验组上述指标水平较对照组显著改善;治疗前后两组间和本组内FBG、胰岛素、Hb Alc水平差异均无统计学意义;治疗后FIB、D-二聚体和hs-CRP水平均显著改善,且治疗后试验组FIB、D-二聚体和hs-CRP水平改善幅度均明显优于对照组;组间不良反应无显著差异。结论:贝前列素钠联合缬沙坦对糖尿病肾病具有良好的肾脏保护作用,可广泛应用。
OBJECTIVE: To observe the effect of reducing or reversing proteinuria in diabetic nephropathy with beraprost sodium tablets and valsartan in the treatment of early diabetic nephropathy. Methods: 48 patients with early diabetic nephropathy were selected and randomly divided into experimental group and control group. All patients were given valsartan treatment, the other oral test beraprost sodium. BUN, Scr, 24h UAlb, FBG, insulin, HbAlc and other indicators before and after treatment were measured and adverse reactions were counted. Results: The levels of BUN, Scr and 24h UAlb in the two groups before treatment were not significantly different. After treatment, the levels of BUN, Scr and 24h UA in the two groups were significantly improved after treatment, and the levels of these indexes in the experimental group were significantly improved after treatment compared with those in the control group. There were no significant differences in FBG, insulin and Hb Alc levels between the two groups. After treatment, the levels of FIB, D-dimer and hs-CRP were significantly improved. After treatment, FIB, D-dimer and hs- CRP levels were significantly better than the control group; no significant differences between groups. Conclusion: Beraprost sodium combined with valsartan has a good renal protective effect on diabetic nephropathy and can be widely used.